Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Shareholder Meeting (September 2026)
10 slides from Recce Pharmaceuticals's shareholder meeting presentation, Sep 2, 2026
Slide 1: General Meeting
For personal use only General Meeting ASX:RCE | FSE:R9Q September 2026 0
Slide 2: Disclaimer
Disclaimer For personal use only DISCLAIMER FUTURE MATTERS This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of not purport to contain all the inform
Slide 3: Recce Pharmaceuticals – Company Overview
Recce Pharmaceuticals – Company Overview Recce Pharmaceuticals is a leading, Australian anti-infective company approaching near term commercialisation milestones For personal use only Products address the global healthcare crisis of antibiotic resistance: working faster than traditional antibiotics
Slide 4: Board and Management Structure
Board and Management Structure Dr John Prendergast – Chairman Michele Dilizia – Executive Director & Chief Scientific Officer For personal use only BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM US-based, current Chairman and Co-founder of
Slide 5: Registrational Phase 3 Clinical Trial - Indonesia
Registrational Phase 3 Clinical Trial - Indonesia Study Title: Phase 3, Double-blind, Placebo-Controlled Study of R327 Topical Gel for the Treatment of Diabetic Foot Ulcer Infections For personal use only Population Intervention Up to 310 participants will be enrolled who present with a mild diabeti
Slide 6: Phase 3 DFI Clinical Trial Expands in Australia
Phase 3 DFI Clinical Trial Expands in Australia HREC approves protocol amendment adding randomised, active-controlled, non-inferiority + superiority component For personal use only Randomised, active-controlled, non-inferiority design and includes a superiority analysis Study Design Randomised betwe
Slide 7: Phase 3 DFI Clinical Trial Expands in Australia & Indonesia
Phase 3 DFI Clinical Trial Expands in Australia & Indonesia HREC approves protocol amendment adding randomised, active-controlled, non-inferiority component For personal use only ~80% HREC approval significantly expands DFI Total Mild + Moderate patient pool from Mild to Mild + Moderate 47% Mild DFI
Slide 8: Large Addressable Market
Large Addressable Market The global diabetic foot infection (DFI) market represents a substantial burden on global healthcare systems For personal use only INDONESIA MENA GLOBAL US$5.8B >20 million >84 million >589 million adults in Indonesia with adults in MENA region adults globally with Est. glob
Slide 9: Program Pipeline driven by 1st approval in Diabetic Foot Infections
Program Pipeline* driven by 1st approval in Diabetic Foot Infections 2026 2027 2028 2029 2030 For personal use only Phase 3 Interim Data Readout - 155 patients R327 Topical Diabetic Foot Ulcer Infection GEL INDONESIA/ASEAN Indo trial data used for global R327G R327G registration strategy Registered
Slide 10: Thank you
For personal use only Thank you recce.com.au
Recce Pharmaceuticals — Shareholder Meeting (September 2026) on 6ix